[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:solid-neoplasm:erbb2-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Solid Neoplasm","ERBB2 Gene",28,[8,16,23,29,36,42,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,150,156,161,167,173],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06241456","FT825\u002FONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.070504Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07228247","A Phase Ⅰ\u002FⅡa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:23.582895Z","2026-05-05T02:43:28.487784Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05957536","A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors",[12],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.210943Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT05673928","A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)",[33],"Phase 2","2026-08-26T02:16:48.735701Z","2026-05-05T02:43:28.183681Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06311214","Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)",[33],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:28.118704Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06126276","Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)",[33],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:27.322411Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04585958","Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer",[12],"2026-08-26T02:17:21.315591Z","2026-05-05T02:43:27.053677Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06616766","A Phase 1\u002F2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946",[20],"2026-08-26T02:18:15.214990Z","2026-05-05T02:35:31.680026Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06581432","Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations",[33],"2026-08-26T02:18:49.989941Z","2026-04-29T02:57:57.144755Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05861895","HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors",[12],"2026-08-26T02:15:41.377360Z","2026-04-29T02:57:57.119787Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05315700","Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration",[20],"2026-08-26T02:16:45.157238Z","2026-05-05T02:43:28.704037Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06804824","A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:17:13.277148Z","2026-05-05T02:43:28.192980Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06364410","Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:28.188138Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07192432","Gene Therapy for HER-Positive Cancer (SENTRY-HER2)",[20],"2026-08-26T02:15:50.539717Z","2026-05-05T02:43:28.103874Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT07361562","A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors",[12],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.101090Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT05523947","Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor",[20],"2026-08-26T02:16:51.982021Z","2026-04-29T02:57:57.117371Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06293898","Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors",[12],"2026-08-26T02:16:23.080181Z","2026-07-24T01:27:14.888332Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT05872295","IKS014 in Advanced Solid Tumors That Express HER2",[12],"2026-08-26T02:19:16.454910Z","2026-07-05T05:32:16.816198Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05150691","A Phase 1\u002F2a Study of DB-1303\u002FBNT323 in Advanced\u002FMetastatic Solid Tumors",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.396080Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06695845","A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",[33],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.744064Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT03740256","Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",[12],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:28.644039Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT05417594","Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",[20],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.529406Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06760819","A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",[33],"2026-08-26T02:17:10.213717Z","2026-05-05T02:43:26.692781Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT06253871","A Phase 1\u002F1b Study of IAM1363 in HER2 Cancers",[12],"2026-08-26T02:18:31.944757Z","2026-05-05T02:35:31.700916Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":94,"content_modified":160},"NCT05765851","A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors",[12],"2026-06-14T18:39:22.235878Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT04899908","Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases",[33],"2026-08-26T02:16:07.529922Z","2026-06-17T19:21:16.685075Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT07124000","DESTINY-PANTUMOUR04",[],"2026-08-26T02:15:24.145250Z","2026-05-13T02:55:06.658082Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT06802172","Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial",[],"2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.189355Z"]